QuidelOrtho Corp (QDEL) · Aug 6, 2026 · Company update

Full-year outlook sharply cut as China weakness and soft respiratory demand deepen

Full-year outlook sharply cut as China weakness and soft respiratory demand deepen

The key expectation was the May 5 outlook, and it has been materially reset. No dependable full-year published consensus is available in the supplied context, so the company’s previous guidance was the clearest standing expectation; management had previously reiterated that 2026 revenue, EBITDA and EPS should remain broadly on track.

MetricUpdated guidancePrevious guidanceChange in midpoint
Reported revenue$2.52–$2.60B$2.70–$2.75Bapproximately -5.7%
Adjusted EBITDA$540–$560M$615–$630Mapproximately -11.6%
Adjusted EBITDA margin21%–22%23%down about 1 percentage point
Adjusted diluted EPS$0.65–$0.90$1.80–$2.00approximately -59%
Free cash flowWithdrawn$100–$120Mno current target

(Guidance table)

The second quarter itself was not the main problem; the forward reset was. Revenue rose 2.8% year over year to $630.9 million, while adjusted EBITDA increased to $129.3 million from $106.8 million, lifting the margin to 20.5% from 17.4%. But the six-month picture remained weaker: revenue fell 4.3% to $1.25 billion and adjusted EBITDA declined 10.7% to $238.0 million. (Financial highlights; Adjusted EBITDA reconciliation)

China and respiratory demand are now large enough to overwhelm healthier core trends. China revenue fell 18.7% reported and 23.3% in constant currency, while revenue outside China grew 6.1% reported and 5.9% in constant currency. Labs excluding China grew 9.0%, and Point of Care rose 16.3%, but Donor Screening and Molecular Diagnostics declined sharply and management cited a softer global respiratory environment. (Segment results; China revenue; Labs excluding China)

The cash signal is worse than the adjusted earnings signal. Operating cash flow was negative $143.6 million in the first six months versus positive $18.8 million a year earlier, cash fell to $123.4 million from $169.8 million at year-end, and current borrowings rose to $355.7 million from $178.3 million. With free-cash-flow guidance withdrawn, investors lose visibility just as working-capital pressure and balance-sheet leverage are becoming more important. (Cash Flow statement; Balance Sheet)

Net read: a broad negative revision, not merely a quarterly miss. The filing preserves evidence of strength outside China, but the roughly 6% revenue reset, roughly 12% EBITDA reset, nearly 60% EPS reduction and withdrawal of cash-flow guidance substantially lower the earnings and cash-conversion expectations investors had entering the release.

Original filing on SEC EDGAR

More QuidelOrtho Corp news

Full-year outlook sharply cut as China weakness and soft respiratory demand deepen | QDEL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.